Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
Murata Y, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Takeshita M, Ito K, Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Murata Y, et al. Among authors: yamaguchi t, yamaguchi k. JTO Clin Res Rep. 2023 Oct 20;4(12):100593. doi: 10.1016/j.jtocrr.2023.100593. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046378 Free PMC article.
Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.
Matsuzawa R, Morise M, Ito K, Hataji O, Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M. Matsuzawa R, et al. Among authors: yamaguchi t. EClinicalMedicine. 2023 Nov 10;66:102303. doi: 10.1016/j.eclinm.2023.102303. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38034077 Free PMC article.
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y. Imai H, et al. Among authors: yamaguchi t. Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195. Jpn J Clin Oncol. 2024. PMID: 38271158 Free PMC article.
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T, Iwashima A, Sugisaka J, Miura Y, Tanaka H, Miyawaki T, Yokouchi H, Miura K, Saito R, Saito G, Kamoshida T, Uchinami Y, Kato T, Kobayashi K, Asahina H. Furuta M, et al. Among authors: yamaguchi t. Cancer Sci. 2024 Nov;115(11):3705-3717. doi: 10.1111/cas.16340. Epub 2024 Sep 15. Cancer Sci. 2024. PMID: 39278260 Free PMC article.
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Shibaki R, Fujimoto D, Miyauchi E, Tsukita Y, Nakachi I, Arai D, Sakata Y, Shingu N, Shimokawa T, Kijima T, Tamiya M, Kawana S, Hara S, Saito G, Sato Y, Yokoyama T, Sakata S, Taniguchi Y, Hata A, Matsumoto H, Yamaguchi T, Yamamoto N. Shibaki R, et al. Among authors: yamaguchi t. Lung Cancer. 2024 Oct;196:107958. doi: 10.1016/j.lungcan.2024.107958. Epub 2024 Sep 19. Lung Cancer. 2024. PMID: 39312871 Clinical Trial.
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H. Sugisaka J, et al. Among authors: yamaguchi t. Lung Cancer. 2024 Dec 9;199:108056. doi: 10.1016/j.lungcan.2024.108056. Online ahead of print. Lung Cancer. 2024. PMID: 39674045
[Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer -- a retrospective analysis].
Yamaguchi T, Nakanishi T, Hayashi M, Uozu S, Okamura T, Morishita M, Takeyama T, Minezawa T, Morikawa S, Niwa Y, Mieno Y, Kato A, Hoshino T, Isogai S, Okazawa M, Imaizumi K. Yamaguchi T, et al. Gan To Kagaku Ryoho. 2015 Feb;42(2):183-7. Gan To Kagaku Ryoho. 2015. PMID: 25743136 Japanese.
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Uemura T, et al. Among authors: yamaguchi t. Cancer Med. 2023 Dec;12(23):21097-21110. doi: 10.1002/cam4.6668. Epub 2023 Nov 10. Cancer Med. 2023. PMID: 37948122 Free PMC article.
9,387 results